

# Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

## 1 Guideline

Joint replacement (primary): hip, knee and shoulder

## 2 List of modelling questions

<b>Review question(s) by scope area</b>	<b>In adults having elective joint replacement, what is the clinical and cost effectiveness of tranexamic acid (TXA) for minimising blood loss from surgery?</b>
Population	Adults having primary elective joint replacement
Interventions and comparators considered for inclusion	<ul style="list-style-type: none"> <li>• Intraarticular (IA) TXA</li> <li>• Intravenous (IV) TXA</li> <li>• Oral TXA</li> <li>• IA and IV TXA</li> <li>• IA and oral TXA</li> </ul>
Perspective	Interventions with health outcomes in the NHS setting (UK NHS and PSS costs)
Outcomes	Transfusion events
Type of analysis	Network meta-analysis with cost analysis
Issues to note	Placebo and no treatment were excluded from the analysis as the use of TXA in any form is clinically and cost effective practice in comparison. Hip and knee studies are combined in this analysis as blood loss between the procedures is expected to be the same. Blood loss for shoulder replacements is expected to be less, however, no includable studies were found.